B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models

Samuel Kim*, Zvi G. Fridlender, Robert Dunn, Marilyn R. Kehry, Veena Kapoor, Aaron Blouin, Larry R. Kaiser, Steven M. Albelda

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

The role played by B cells in cancer biology is complex and somewhat controversial. Previous studies using genetically engineered mice suggest that B cells may be immunosuppressive and inhibit tumor rejection. However, the effects of B-cell depletion employing an antibody in mice bearing solid tumors has not been tested owing to difficulties in making an effective antimouse CD20 antibody (similar to rituximab). Injection of a newly developed antimouse CD20 antibody was effective in depleting circulating B cells from blood and lymph nodes, although depletion was less complete in the spleen. B-cell depletion slowed the growth of new solid tumors (not expressing CD20) and retarded the growth of established tumors but did not induce tumor regression. However, when the antibody was combined with an active immunotherapy approach using an adenovirus vaccine expressing the human papilloma virus-E7 gene (Ad.E7) in mice bearing TC1 tumors (murine lung cancer cells expressing human papilloma virus-E7), we noted enhanced antitumor effects and increased numbers of tetramer/CD8 T cells within the spleens and activated CD8 T cells within tumors. B-cell depletion using an anti-CD20 antibody was thus effective in retarding tumor growth in multiple solid tumor models and augmenting immunotherapy in a tumor vaccine model. These studies raise the possibility that B-cell depletion may be a useful adjunct in human immunotherapy trials.

Original languageAmerican English
Pages (from-to)446-457
Number of pages12
JournalJournal of Immunotherapy
Volume31
Issue number5
DOIs
StatePublished - Jun 2008
Externally publishedYes

Keywords

  • Antibody therapy
  • B cells
  • Immunosuppression
  • Lung cancer
  • Mesothelioma
  • Tumor immunology

Fingerprint

Dive into the research topics of 'B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models'. Together they form a unique fingerprint.

Cite this